These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24969795)

  • 21. Chemical-shift and diffusion-weighted magnetic resonance imaging of thymus in myasthenia gravis: usefulness of quantitative assessment.
    Priola AM; Priola SM; Giraudo MT; Gned D; Giardino R; Marci V; Errico L; Veltri A
    Invest Radiol; 2015 Apr; 50(4):228-38. PubMed ID: 25478741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
    Mannelli L; Kim S; Hajdu CH; Babb JS; Clark TW; Taouli B
    AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffusion kurtosis imaging to assess response to treatment in hypervascular hepatocellular carcinoma.
    Goshima S; Kanematsu M; Noda Y; Kondo H; Watanabe H; Bae KT
    AJR Am J Roentgenol; 2015 May; 204(5):W543-9. PubMed ID: 25905960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular Carcinoma: In Vivo Evaluation of Water Percentage as a Prognostic Biomarker Using Magnetic Resonance Imaging 3D-VIBE Multiecho Dixon.
    Wang M; Yuan F; Wei Y; Xia C; Hu F; Song B
    Cancer Biother Radiopharm; 2018 Sep; 33(7):300-306. PubMed ID: 30109954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma.
    Nishie A; Tajima T; Asayama Y; Ishigami K; Kakihara D; Nakayama T; Takayama Y; Okamoto D; Fujita N; Taketomi A; Yoshimitsu K; Honda H
    Eur J Radiol; 2011 Nov; 80(2):e29-33. PubMed ID: 20619566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffusion-weighted imaging during MR-guided radiofrequency ablation of hepatic malignancies: analysis of immediate pre- and post-ablative diffusion characteristics.
    Hoffmann R; Rempp H; Schraml C; Schwenzer N; Grözinger G; Blumenstock G; Rothgang E; Pereira PL; Claussen CD; Clasen S
    Acta Radiol; 2015 Aug; 56(8):908-16. PubMed ID: 25182804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging.
    Sahin H; Harman M; Cinar C; Bozkaya H; Parildar M; Elmas N
    J Vasc Interv Radiol; 2012 Feb; 23(2):241-7. PubMed ID: 22019180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Significance of Apparent Diffusion Coefficient in Hepatocellular Carcinoma Patients treated with Stereotactic Ablative Radiotherapy.
    Lo CH; Huang WY; Hsiang CW; Lee MS; Lin CS; Yang JF; Hsu HH; Chang WC
    Sci Rep; 2019 Oct; 9(1):14157. PubMed ID: 31578433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization.
    Dong S; Ye XD; Yuan Z; Xu LC; Xiao XS
    Eur J Radiol; 2012 Mar; 81(3):472-7. PubMed ID: 21296517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of malignant and benign renal lesions using diffusion-weighted MRI with multiple b values.
    Erbay G; Koc Z; Karadeli E; Kuzgunbay B; Goren MR; Bal N
    Acta Radiol; 2012 Apr; 53(3):359-65. PubMed ID: 22334870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma.
    Nakanishi M; Chuma M; Hige S; Omatsu T; Yokoo H; Nakanishi K; Kamiyama T; Kubota K; Haga H; Matsuno Y; Onodera Y; Kato M; Asaka M
    Ann Surg Oncol; 2012 Apr; 19(4):1302-9. PubMed ID: 21927976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma.
    Kamel IR; Reyes DK; Liapi E; Bluemke DA; Geschwind JF
    J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):49-56. PubMed ID: 17296704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of apparent diffusion coefficients in evaluating the response of vestibular schwannomas to Gamma Knife surgery.
    Chuang CC; Chang CS; Tyan YS; Chuang KS; Tu HT; Huang CF
    J Neurosurg; 2012 Dec; 117 Suppl():63-8. PubMed ID: 23205791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary study of apparent diffusion coefficient assessment after ion beam therapy for hepatocellular carcinoma.
    Kanamoto M; Miyati T; Terashima K; Suga D; Fuwa N
    Radiol Phys Technol; 2016 Jul; 9(2):233-9. PubMed ID: 27055451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusion-weighted MRI Before and After Robotic Radiosurgery (Cyberknife®) in Primary and Secondary Liver Malignancies: A Pilot Study.
    Schmid-Tannwald C; Strobl FF; Theisen D; Muacevic A; Stintzing S; Reiser MF; Trumm CG
    Technol Cancer Res Treat; 2015 Apr; 14(2):191-9. PubMed ID: 24502549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion-weighted MRI in renal cell carcinoma: a surrogate marker for predicting nuclear grade and histological subtype.
    Goyal A; Sharma R; Bhalla AS; Gamanagatti S; Seth A; Iyer VK; Das P
    Acta Radiol; 2012 Apr; 53(3):349-58. PubMed ID: 22496427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microvascular invasion in small hepatocellular carcinoma: is it predictable with preoperative diffusion-weighted imaging?
    Xu P; Zeng M; Liu K; Shan Y; Xu C; Lin J
    J Gastroenterol Hepatol; 2014 Feb; 29(2):330-6. PubMed ID: 24033853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.
    Seyal AR; Gonzalez-Guindalini FD; Arslanoglu A; Harmath CB; Lewandowski RJ; Salem R; Yaghmai V
    Hepatology; 2015 Oct; 62(4):1111-21. PubMed ID: 25999236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
    Kamel IR; Bluemke DA; Eng J; Liapi E; Messersmith W; Reyes DK; Geschwind JF
    J Vasc Interv Radiol; 2006 Mar; 17(3):505-12. PubMed ID: 16567675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Vouche M; Kulik L; Atassi R; Memon K; Hickey R; Ganger D; Miller FH; Yaghmai V; Abecassis M; Baker T; Mulcahy M; Nayar R; Lewandowski RJ; Salem R
    Hepatology; 2013 Nov; 58(5):1655-66. PubMed ID: 23703789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.